Business Context and Reporting Period
This Form 8-K, filed on January 22, 2013, by Cactus Ventures, Inc. (the registrant), concerns the recent reverse merger with Actinium Pharmaceuticals, Inc. ("Actinium"). The filing reports on the termination of a private equity offering by Actinium that concluded on December 19, 2012, following the closing of the reverse merger on December 28, 2012.
Key Financial Metrics
The filing details the completion of a private offering raising a total of $5.1 million. The capital raise involved the issuance of:
- 9.3 million shares of Actinium common stock.
- Warrants to purchase 9.3 million shares exercisable for 120 days at $0.55 per share.
- Warrants to purchase approximately 4.6 million shares exercisable for 5 years at $0.825 per share.
These securities were exchanged for equivalent Cactus securities. The filing does not provide specific data on revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The primary material event is the termination of the private offering following the successful sale of $5.1 million in equity. This filing updates and supersedes previous press releases dated December 26, 2012, and January 3, 2013, regarding the offering status. The reverse merger transaction closed on December 28, 2012, integrating Actinium's securities into Cactus Ventures.
Guidance, Outlook, and Risks
Cactus Ventures indicated it may raise additional capital in future private offerings. However, any future securities will not be registered under the Securities Act of 1933 and cannot be sold in the United States absent registration or an applicable exemption. The filing includes standard forward-looking statements regarding the company's ability to raise capital and future financial performance, noting that actual results may differ materially due to known and unknown risks. The company assumes no obligation to update these statements.
Investor Verification Checklist
- Verify the exchange of Actinium securities for Cactus securities as described in the reverse merger.
- Review Amendment No. 2 to the Current Report on Form 8-K filed by Cactus on January 28, 2013, for more detailed transaction information.
- Confirm the status of any future capital raising efforts and their compliance with securities registration requirements.
- Assess the impact of the $5.1 million capital raise on the company's liquidity and operational runway, noting that specific financial statements are not included in this filing.